HC Wainwright Predicts BioNTech's Q3 Earnings (NASDAQ:BNTX)

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings estimates for shares of BioNTech in a report issued on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.12) per share for the quarter, down from their previous forecast of ($1.10). HC Wainwright has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

BNTX has been the subject of a number of other reports. Truist Financial reaffirmed a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Morgan Stanley reduced their price target on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Citigroup reaffirmed a "buy" rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Finally, BMO Capital Markets upped their target price on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $137.86.

BioNTech Trading Up 0.4%

BNTX traded up $0.39 during trading on Friday, reaching $107.90. The company had a trading volume of 563,695 shares, compared to its average volume of 938,919. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. The business has a 50 day simple moving average of $102.94 and a 200-day simple moving average of $106.95. The stock has a market cap of $25.94 billion, a P/E ratio of -31.74 and a beta of 1.29. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise acquired a new stake in BioNTech in the first quarter valued at approximately $36,000. Jones Financial Companies Lllp lifted its position in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares during the last quarter. Banque Transatlantique SA acquired a new stake in BioNTech in the 1st quarter valued at approximately $80,000. Quintet Private Bank Europe S.A. boosted its holdings in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after acquiring an additional 700 shares during the period. Finally, Allianz SE acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $90,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.